Basal cell naevus syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:24 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Basal cell naevus syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Sonidegib for Patients with Nevoid Basal Cell Carcinoma Syndrome and Sporadic Basal Cell Carcinoma https://clinicaltrials.eu/trial/study-of-sonidegib-for-patients-with-nevoid-basal-cell-carcinoma-syndrome-and-sporadic-basal-cell-carcinoma/ Wed, 29 Apr 2026 15:03:04 +0000 https://clinicaltrials.eu/trial/study-of-sonidegib-for-patients-with-nevoid-basal-cell-carcinoma-syndrome-and-sporadic-basal-cell-carcinoma/ This clinical trial is focused on studying the effects of a medication called Sonidegib on two types of skin conditions: Nevoid Basal Cell Carcinoma Syndrome (also known as Gorlin syndrome) and sporadic Basal Cell Carcinoma (BCC). These conditions involve the development of skin cancer, with Gorlin syndrome being a genetic disorder that leads to multiple skin cancers, while sporadic BCC occurs randomly and is not inherited. The treatment being tested is Odomzo 200 mg hard capsules, which contain the active substance Sonidegib.

The purpose of the study is to observe how well patients with these conditions respond to the treatment over a period of 40 weeks. Initially, participants will take Sonidegib daily for 16 weeks. After this period, the dosing schedule will change to a less frequent, pulsed schedule for the remaining 24 weeks. This approach aims to assess the treatment’s effectiveness and how well patients can adhere to the medication regimen.

The study will monitor various outcomes, including the rate at which participants discontinue the treatment due to side effects, the overall response rate of the skin cancer to the treatment, and the duration of response. Additionally, the study will evaluate the quality of life of participants using a questionnaire called the EORTC QLQ C30 at different stages of the treatment. The trial is expected to conclude by June 2027.

]]> Study on Patidegib Gel for Reducing Basal Cell Carcinomas in Adults with Gorlin Syndrome https://clinicaltrials.eu/trial/study-on-patidegib-gel-for-reducing-basal-cell-carcinomas-in-adults-with-gorlin-syndrome/ Wed, 29 Apr 2026 14:30:15 +0000 https://clinicaltrials.eu/trial/study-on-patidegib-gel-for-reducing-basal-cell-carcinomas-in-adults-with-gorlin-syndrome/ This clinical trial is focused on studying a condition known as Gorlin Syndrome, which is a genetic disorder that can lead to the development of multiple skin cancers called Basal Cell Carcinomas (BCCs). The study is testing a treatment called Patidegib Gel 2%, which is applied directly to the skin. The purpose of the study is to evaluate how effective and safe this gel is in reducing the number of BCCs that develop on the face of adults with Gorlin Syndrome.

Participants in the study will be randomly assigned to use either the Patidegib Gel or a Vehicle Gel, which does not contain the active medication. The study will last for 12 months, during which participants will apply the gel twice daily to their face. Throughout the study, the number of new BCCs will be monitored, along with any changes in the size of existing BCCs and any side effects experienced by the participants.

The study aims to determine if Patidegib Gel can effectively reduce the burden of BCCs in individuals with Gorlin Syndrome, potentially offering a new way to manage this condition. Participants will be closely monitored by healthcare professionals to ensure their safety and to gather data on the gel’s effectiveness in preventing new BCCs from forming.

]]>